PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
![Quantitative [<sup>18</sup>F]-Naf-PET-MRI Analysis for the Evaluation of Dynamic Bone Turnover in a Patient with Facetogenic Low Back Pain](https://visualize.jove.com/wp-content/cache/webp/776ddc8695e4f7aa0d6044903df0f878.webp)
View abstract on PubMed
Summary
This summary is machine-generated.Parathyroid hormone (PTH) analogs, teriparatide and abaloparatide, effectively reduce fracture risk in osteoporosis patients. Abaloparatide shows greater efficacy for non-vertebral and hip fractures compared to teriparatide, with both agents demonstrating favorable safety profiles.
Area Of Science
- Endocrinology and Bone Metabolism
- Pharmacological Interventions for Osteoporosis
Background
- Osteoporosis is characterized by decreased bone mineral density and deteriorating bone structure, increasing fracture risk, especially in aging individuals.
- Randomized controlled trials (RCTs) confirm the efficacy of parathyroid hormone type 1 (PTH1) receptor agonists, teriparatide and abaloparatide, in reducing fractures, but real-world evidence (RWE) is limited.
Purpose Of The Study
- To systematically review and compare the anti-fracture efficacy of teriparatide and abaloparatide against each other and other osteoporosis treatments.
- To evaluate the efficacy using both randomized controlled trials (RCTs) and real-world evidence (RWE).
- To assess the safety profiles of these agents.
Main Methods
- Systematic literature search of Medline, Embase, and Cochrane databases up to May 2024 for RCTs and RWE studies.
- Inclusion criteria focused on studies reporting fracture reduction (vertebral, non-vertebral, hip, or all) as a primary endpoint.
- Network meta-analysis (NMA) including pairwise meta-analyses and Bayesian NMA; safety assessment using MedDRA adverse event classification.
Main Results
- Both teriparatide and abaloparatide significantly reduced vertebral and non-vertebral fractures compared to placebo.
- Abaloparatide demonstrated superior efficacy over teriparatide for non-vertebral fractures (OR: 0.87) and hip fractures (OR: 0.81).
- In NMA, both PTH1 analogs outperformed placebo, raloxifene, and calcitonin for vertebral fractures; teriparatide also surpassed denosumab and risedronate. Abaloparatide was superior for non-vertebral fractures, while teriparatide showed superiority only over alendronate or placebo.
Conclusions
- PTH1 receptor agonists are effective in reducing fracture risk, with abaloparatide showing enhanced benefits for non-vertebral and hip fractures compared to teriparatide.
- Both agents possess comparable safety profiles to other osteoporosis treatments, with no increased cardiovascular risk.
- Teriparatide and abaloparatide represent valuable therapeutic options for managing osteoporosis, particularly in high-risk patient populations.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Treatment for a fracture is based on the type of break, the bone affected, and the patient's age.
Minor fractures with no bone displacement are treated by immobilizing the fractured bone using a cast or splint. However, in the case of fractures with displaced bones, the broken bones are repositioned before immobilization to ensure successful healing without deformation and loss of function. The realignment of fractured bone ends is performed through a process called reduction. If the...
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
Hormonal Control of Bone Remodeling
Parathyroid hormone (PTH) maintains homeostatic control of blood calcium levels by regulating bone resorption. PTH is...
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...